Clinical Trial Update: Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial update of zimberelimab (AB122) with domvanalimab (AB154) in PD-1 relapsed/refractory melanoma; the study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Domvanalimab (domvanalimab)
• Zimberelimab (zimberelimab)

Snippet

Sponsor: Diwakar Davar | Conditions: Melanoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING